This expansion reflects the momentum of our joint work and strengthens our ability to advance a broader portfolio of disease-modifying programs, grounded in causal biology and built to move with speed and precision for patients living with ALS.
Learn more by viewing the slideshow.
including processes linked to TDP-43 mislocalization, a hallmark of pathology in nearly 97% of ALS patients.
Take a deep dive in our latest Perspectives blog post: www.insitro.com/news/rewriti...
Powered by insitro’s Virtual Human™ causal discovery platform, this work integrates massive-scale, human-derived cell data with machine learning to map disease drivers with unprecedented resolution,
insitro is proud to deepen our work in ALS with the expansion of our strategic collaboration with @bms-news.bsky.social and the nomination of two additional therapeutic targets discovered through insitro’s AI-driven Virtual Human™ platform.
Read our press release: www.insitro.com/news/insitro...
We announced Joe Hand as insitro’s Chief People Officer.
Joe brings a wealth of experience scaling life sciences organizations. As our AI & biology platform expands & our pipeline advances, Joe will lead our global people strategy to support our next phase of growth. www.insitro.com/news/insitro...
insitro’s David Lloyd reported the first-ever genome-wide association study of brown adipose tissue & a differentiated target w/ anti-obesity effects, the modulation of which reduced body weight 15% & fat mass 25% in preclinical models while preserving lean tissue. www.insitro.com/news/insitro...
insitro founder and CEO Daphne Koller sat down with BiotechTV during #JPM26. Daphne discusses how AI is helping insitro accelerate drug discovery and translate data into meaningful therapeutic insight. www.biotechtv.com/post/insitro...
insitro acquired CombinAbleAI & launched TherML™, completing a unified, modality-agnostic AI platform for therapeutic design across small molecules, biologics, & oligonucleotides, optimizing potency & developability from the start. 🔗 www.insitro.com/news/combina...
🔗 www.insitro.com/news/introdu...
insitro will present at #JPM26. CEO Daphne Koller will share progress across our AI-enabled discovery engine & programs advancing toward the clinic, w/ additional participation from our leadership team throughout the week.
www.insitro.com/news/insitro...
New research in Nature Communications validates insitro’s POSH platform for mapping gene function using pooled CRISPR & self-supervised ML.
By preserving rich cellular morphology, POSH reveals biology conventional approaches miss.
🔗 www.nature.com/articles/s41...
Samuel Sances will be at Intl. Symposium on ALS/MND Sunday to share work from collab. w/ @bristolmyerssquibb.bsky.social. #ML on 200+ patient-derived motor neuron lines, ID'd genes that rescue cellular function, reverse TDP-43 pathology & restore STMN2. symposium.mndassociation.org
#DrugDiscovery
insitro is proud to welcome Stephen Hitchcock (ex-Takeda CSO) and Vijay Pande (VZVC co-founder, formerly on our Board) as scientific advisors, focused on translating AI-predicted targets into clinical drug candidates through our ChemML platform. www.insitro.com/news/insitro...
From genetic correlation to validated mechanism. Our #MASLD program (CTRO-1013) targeting IRS1 was named a Poster of Distinction at #AASLD2025. We used AI on multimodal data from 263K people to find the target, now validated & advancing to IND-enabling studies. www.insitro.com/news/reveali...
Genomic data offers correlation in abundance. Causation requires experimental proof at every step. Join insitro at #AASLD2025. On Monday, 1pm, Poster 4013: learn how platform integration of AI, patient-derived biology & staged validation narrow the gap for MASLD therapeutics.
We extended our collaboration w/ @bristolmyerssquibb.bsky.social to advance our #ALS target into AI-enabled #drugdiscovery. The next phase is w/ our ChemML™ platform, turning discoveries➡️medicines w/ AI-driven modeling, medicinal chemistry, & structural biology. www.insitro.com/news/insitro...
We’re @ #ASHG to share our work that uses high-content phenotypic data, genetics & AI/ML to unblock new biology.
@sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD
@twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk
...including members of Lilly TuneLab, a new platform designed to empower biotechs with cutting-edge ML tools to transform medicine discovery. This model has the potential to give researchers the ability to zero in on drug-like chemical structures at the earliest stages.
Through this partnership, we’ll train advanced #ML models on Lilly’s rich preclinical dataset to overcome a longstanding problem in drug discovery. It will be available to insitro and our partners, Lilly and their partners...
We’re excited to announce a new collaboration with @elilillyandcompany.bsky.social to build next-gen #machinelearning models for small molecule design. www.insitro.com/news/insitro...
Gabriel blends biology & ML to drive small molecule #drugdevelopment. From melanoma research to a Master’s at UCL to presenting insitro’s KinDEL dataset @ ICML, his career advances drug discovery w/ scalable data & predictive modeling. Read his Meet the insitrocyte below. arxiv.org/abs/2410.08938
It means partnering with BMS, Eli Lilly and Insight at London’s Moorfields Eye Hospital – organizations that also value finding new ways to deploy AI for patients who can’t afford to wait. Cheers to 7 years, to our team, our partners, and the belief that better #drugdiscovery is on the horizon. ✨
It means building the world’s largest cellular data factory with > 10 petabytes. It means a tech stack and software powered by 192 GPUs. It means a bilingual culture where learning each other’s discipline is the starting point.
7️⃣ years of using AI differently. That means looking where others don’t. . . or can’t.
@keystonesymposia.bsky.social’s joint conference is coming up! insitro’s Director Max Salick will present at “The Digital Era in Neurodegeneration & Neuroinflammation” to share recent research & technological advances on our POSH platform. Learn more: www.keystonesymposia.org/conferences/...
Today insitro announces an exciting new collaboration with insighteyehub.bsky.social at Moorfields Eye Hospital, London, through the development of a novel #AI foundation model to identify and to support #drugdiscovery. Learn more: www.businesswire.com/news/home/20...
Join insitro CEO & founder Daphne Koller at WIRED Health in London Tuesday, March 18 as she takes the keynote stage! 📣 Daphne will be sharing an inside look at how insitro’s approach to #drugdiscovery is building a pipeline of high-conviction targets through #machinelearning, #AI & data at scale.
Thanks to the SFBT for including insitro CEO and founder Daphne Koller in their Newsmakers 100 list, recognizing the great partnerships and developments we announced with both
@elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...
Our insitrocytes are the heartbeat of our shared vision. Together, as builders, scientists, engineers, we solve complex challenges every day, laser-focused on delivering better medicines for patients. Hear directly from some of our colleagues about how we work.
Visit www.insitro.com/people/.
As our debut Bluesky post, we’re excited to share our new paper (first author Zachary McCaw) in HGG Advances on scrutinizing the practice of using a ratio trait (numerator / denominator) for GWAS. www.cell.com/hgg-advances...
